recent news

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 Inflammatory bowel disease (IBD) represents a multi-billion dollar market opportunity with current therapies achieving a clinical remission rate of less than 20% on average   Carlsbad, CA – September 5, 2023 [...]

Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation

MONTREAL--(BUSINESS WIRE)--Giiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000. This financing will support the development of GT-2108, an orally administered, gut-restricted, colon-specific PDE4 (phosphodiesterase-4) inhibitor prodrug for [...]

Giiant Pharma Inc. appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry

MONTREAL–(BUSINESSWIRE)–Giiant Pharma Inc., a Montreal biotech company developing gut-restricted drug therapeutics at the pre-clinical stage in gastroenterology, announced the expansion of its research leadership team with the appointment of Christophe Mellon, PhD. Christophe’s rich and varied career path led him to leadership positions in pharmaceutical, biotech, and start-up companies for more than 20 years. Recently, [...]